Kamada (KMDA) Change in Receivables (2012 - 2026)
Kamada (KMDA) posted quarterly Change in Receivables of $1.3 million for Q1 2026, up 291.95% year-on-year from $328611.4 in Q1 2025, and down 70.03% on a QoQ basis from $4.3 million in Q4 2025.
Kamada (KMDA) Change in Receivables (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Change in Receivables for 15 consecutive years, with $1.3 million the latest figure, recorded in Q1 2026.
- Quarterly Change in Receivables rose 291.95% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.4 million (up 174.83% YoY) and the FY2025 annual result came in at -$535000.0, up 72.94% from the prior year.
- Change in Receivables slipped to $1.3 million in Q1 2026 per KMDA's latest filing, from $4.3 million in the prior quarter.
- Over the last five years, Change in Receivables for KMDA reached as high as $10.0 million in Q3 2024 and fell as low as -$7.4 million in Q2 2024.
- A 5-year average of $547165.1 and a median of $6306.0 in 2023 frame the typical range for Change in Receivables.
- The largest YoY upside for Change in Receivables was 183385.58% in 2023 against a maximum downside of 9620.04% in 2023.
- Year by year, Change in Receivables stood at -$3141.0 in 2022, then jumped by 183385.58% to $5.8 million in 2023, then plunged by 190.78% to -$5.2 million in 2024, then surged by 182.24% to $4.3 million in 2025, then tumbled by 70.03% to $1.3 million in 2026.
- According to Business Quant data, Change in Receivables over the past three periods registered $1.3 million, $4.3 million, and -$1.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -78.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 106.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -621.82 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -38.20 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 126.30 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 81.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Kamada | 401.22 Mn | 328.07 Mn | 19.12 Mn | 1.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.29 Mn |
| Mar 31, 2026 | 1.29 Mn |
| Dec 31, 2025 | 4.30 Mn |
| Dec 31, 2025 | 4.30 Mn |
| Sep 30, 2025 | -1.04 Mn |
| Sep 30, 2025 | -1.04 Mn |
| Jun 30, 2025 | -2.11 Mn |
| Jun 30, 2025 | -2.11 Mn |
| Mar 31, 2025 | -671,000.00 |
| Mar 31, 2025 | -671,000.00 |
| Dec 31, 2024 | -5.23 Mn |
| Dec 31, 2024 | -5.23 Mn |
| Sep 30, 2024 | 10.00 Mn |
| Sep 30, 2024 | 10.00 Mn |
| Jun 30, 2024 | -7.37 Mn |
| Jun 30, 2024 | -7.37 Mn |
| Mar 31, 2024 | 610,000.00 |
| Mar 31, 2024 | 610,000.00 |
| Dec 31, 2023 | 5.76 Mn |
| Dec 31, 2023 | 5.76 Mn |